Use of oxygenated cholesterol sulfates for cancers and non-cancerous transformations related to epstein-barr virus

Abstract

Aspects of the present disclosure include methods for treating at least one of cancer and non-cancerous transformation related to Epstein-Barr virus, such as at least one of Hodgkin's lymphoma, soft tissue sarcoma, leiomyosarcoma, nasopharyngeal carcinoma, Burkitt's lymphoma, T-cell lymphoma, gastric carcinoma, invasive breast cancer, and hierarchically organized carcinoma. Hierarchically organized carcinomas include, but are not limited to, pancreatic ductal adenocarcinoma, urothelial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, esophagus cancer, breast cancer, thyroid cancer, oral cancer, cervical cancer, ovarian cancer, and liver cancer. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

1 . A method of treating at least one of cancer related to Epstein-Barr virus and non-cancerous transformation related to Epstein-Barr virus in a subject in need thereof, comprising:
 administering to the subject an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof.   
     
     
         2 . The method of  claim 1 , wherein the at least one of cancer related to Epstein-Barr virus and non-cancerous transformation related to Epstein-Barr virus is at least one cancer related to Epstein-Barr virus. 
     
     
         3 . The method of  claim 2 , wherein the at least one cancer comprises at least one of Hodgkin's lymphoma, soft tissue sarcoma, leiomyosarcoma, nasopharyngeal carcinoma, Burkitt's lymphoma, T-cell lymphoma, gastric carcinoma, invasive breast cancer, and hierarchically organized carcinoma. 
     
     
         4 . The method of  claim 3 , wherein the hierarchically organized carcinoma comprises at least one of pancreatic ductal adenocarcinoma, urothelial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, esophagus cancer, breast cancer, thyroid cancer, oral cancer, cervical cancer, ovarian cancer, and liver cancer. 
     
     
         5 . The method of any one of  claims 1  to  4 , wherein the method comprises administering to the subject an effective amount of 25-hydroxycholesterol-3-sulfate (25HC3S) or salt thereof. 
     
     
         6 . The method of any one of  claims 1  to  5 , wherein the at least one compound is administered in an amount selected from the group consisting of:
 (a) an amount ranging from 0.001 mg/kg/day to 100 mg/kg/day; 
 (b) an amount ranging from 0.1 mg/kg to 100 mg/kg, based on body mass of the subject; and 
 (c) an amount ranging from 1 mg/kg to 10 mg/kg, based on body mass of the subject. 
 
     
     
         7 . The method of any one of  claims 1  to  6 , wherein the administering is performed from once to 3 times per day. 
     
     
         8 . The method of any one of  claims 1  to  7 , wherein the administering comprises at least one of oral administration, enteric administration, sublingual administration, transdermal administration, intravenous administration, peritoneal administration, parenteral administration, administration by injection, subcutaneous injection, and intramuscular injection. 
     
     
         9 . The method of any one of  claims 1  to  8 , wherein the administering comprises administering a pharmaceutical composition comprising the at least one compound and a physiologically acceptable excipient, diluent, or carrier. 
     
     
         10 . The method of  claim 9 , wherein the pharmaceutical composition is formulated in unit dosage form. 
     
     
         11 . The method of any one of  claims 9  or  10 , wherein the pharmaceutical composition is in solid form. 
     
     
         12 . The method of any one of  claims 9  to  11 , wherein the pharmaceutical composition: (a) is in the form of a powder, a tablet, a capsule, or a lozenge; and/or (b) comprises the at least one compound in freeze-dried form together with a bulking agent. 
     
     
         13 . The method of  claim 9  or  10 , wherein the pharmaceutical composition comprises a carrier that is a liquid. 
     
     
         14 . The method of  claim 13 , wherein the at least one compound is solubilized in the liquid or dispersed in the liquid. 
     
     
         15 . The method of  claim 13  or  14 , wherein: (a) the liquid is aqueous; or (b) the liquid is sterile water for injections or phosphate-buffered saline. 
     
     
         16 . The method of any one of  claims 9  and  13  to  15 , wherein the pharmaceutical composition is in a sealed vial, ampoule, syringe, or bag.